Drug data last refreshed 16h ago · AI intelligence enriched Yesterday
HELIUM, USP is an inhalation gas product approved by the FDA in July 2021 under NDA sponsorship by Advanced Solutions Life Sciences. The product's mechanism of action and specific therapeutic indications are not publicly detailed, but it is administered via inhalation in gaseous form. Patient population and clinical utility require further clarification from regulatory or clinical sources.
Product is at peak commercial stage with moderate competitive pressure (30%), suggesting mature market positioning and potential team stability rather than aggressive growth hiring.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
C2 Esophageal Squamous Epithelium Dysplasia
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
HELIUM's critical safety profile and inhalation delivery mechanism will drive demand for specialized MSLs, respiratory specialists, and pharmacovigilance professionals focused on adverse event management and provider education. Career opportunities are primarily in commercial execution and risk management rather than clinical development.